Advertising
Showing 1 to 15 of 502 entries
BUY
They report Tuesday. It's best of breed and should rock the quarter. He's confident it can manage the claims arising from its lawsuit. They have perhaps the drug pipeline in the industry.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly We reiterate JNJ as a TOP PICK. The global consumer care product and health care manufacturer is being considered by the FDA for a COVID-19 vaccine booster. It trades at 24x earnings compared to peers at 28x and pays a decent dividend backed by a payout ratio under 55% of cash flow. Cash reserves continue to grow. We would buy this with a stop loss at $147, looking to achieve $191 -- upside potential over 20%. Yield 2.65% (Analysts’ price target is $190.38)
biotechnology / pharmaceutical
BUY
Steady and boring with a AAA balance sheet and tremendous growth prospects. Boring is good.
biotechnology / pharmaceutical
DON'T BUY
Broadly, pharmaceuticals and healthcare space is not providing a ton of opportunity. Trading at reasonable valuations with 3 divisions. Consumer business is in trouble because more people are going towards generics. Pharma business hasn't seen much tailwind from covid vaccines.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Sep 24/20, Up 18%) Prospects now are better than last year. Vaccine. Consecutive dividend increases. Group lawsuits have been settled. Buy it, put it away, give it to the kids. Attractive at these levels.
biotechnology / pharmaceutical
TOP PICK
Overhang has been the liabilities of class actions. Settlements have eased this. Big pharma, consumer division, and medical devices provide it with balanced growth. Grown its dividend for 59 consecutive years. Safe and steady anchor for your portfolio. Attractive at these levels. Yield is 2.55%. (Analysts’ price target is $188.56)
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Sep 15/20, Up 15%) She's owned this for years and continues to buy this diversified healthcare name. Pharmaceuticals account for roughly 50% of revenue. They continually reinvest in their R&D. Many products are #1 in their categories. Boasts a rare triple-A balance sheet and pays a 2.6% dividend that they've increased for 59 years.
biotechnology / pharmaceutical

Unlock the Weekly Buzzing Stocks

Become a member Or, Sign In
TOP PICK
They are in pharma, medical devices and personal care. They are diversified and can weather many different economic conditions. Elective surgeries are coming back with 57% increase in revenues. Social media mentions are up 58% over the last 24 hours.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Aug 20/20, Up 20%) Has long held this. Pharma, medical devices and personal care are their businesses. Unlike other pharmas companies, with JNJ when one sector lags, the others carry the weight. For example, medical devices (due to few elective surgeries) plunged during Covid, but bounced back 58% in revenues last quarter. JNJ has increased their dividend for the last 40-50 years annually. Great balance sheet, and raised guidance in their last quarter which they also beat. A risk are lawsuits; they could lose a suit in the future and pay big settlements, like $250 million to settle to opiod-addiction suit in New York state.
biotechnology / pharmaceutical
BUY
JNJ's vaccine appears to be the least effective against the new Covid strains. And yet, JNJ benefits from Washington expected to decree booster shots for Covid, so the drug space is benefiting as a whole.
biotechnology / pharmaceutical
PARTIAL BUY
It's not a high-grower. Abbot offers stronger growth, but JNJ offers a very defensive portfolio and a reasonable 18x PE. Also pays a good dividend of around 5%. JNJ is defensive in good and bad times. Over time, they raise their dividend and buyback some shares.
biotechnology / pharmaceutical
BUY

JNJ vs. PG Valuation of 16-17x earnings is cheaper than PG. A healthcare company: medical devices, healthcare, pharma. PG is just consumer products, trading at 23x earnings. More opportunity in JNJ, with a caveat on the talc lawsuits. Medical device side should do well post-Covid. Dividends similar in the 2.5% range.

biotechnology / pharmaceutical
BUY on WEAKNESS
It has been a great long term stock. He would own it if it were a little cheaper. They are in a good sector. The entry point is too expensive, otherwise he would like to own it.
biotechnology / pharmaceutical
BUY

Doesn't own, but likes it. Steady, strong technical chart on the upswing. 17x earnings for a 9% growth rate. Diversified products, strong management. Great for cashflow and long-term growth. He prefers Pfizer and ABBV. See his Top Picks today. Yield is 2.6%.

biotechnology / pharmaceutical
BUY
Great company because of its diversified businesses of pharma, medical devices, and personal care products. Great dividend yield, increased for 54 years in a row. Great free cashflow growth.
biotechnology / pharmaceutical
Showing 1 to 15 of 502 entries

Johnson & Johnson(JNJ-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 27

Neutral - Hold Signals / Votes : 3

Bearish - Sell Signals / Votes : 8

Total Signals / Votes : 38

Stockchase rating for Johnson & Johnson is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Johnson & Johnson(JNJ-N) Frequently Asked Questions

What is Johnson & Johnson stock symbol?

Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N

Is Johnson & Johnson a buy or a sell?

In the last year, 38 stock analysts published opinions about JNJ-N. 27 analysts recommended to BUY the stock. 8 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Johnson & Johnson.

Is Johnson & Johnson a good investment or a top pick?

Johnson & Johnson was recommended as a Top Pick by on . Read the latest stock experts ratings for Johnson & Johnson.

Why is Johnson & Johnson stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Johnson & Johnson worth watching?

38 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.

What is Johnson & Johnson stock price?

On 2021-10-20, Johnson & Johnson (JNJ-N) stock closed at a price of $163.78.